JP2016513643A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513643A5
JP2016513643A5 JP2016501314A JP2016501314A JP2016513643A5 JP 2016513643 A5 JP2016513643 A5 JP 2016513643A5 JP 2016501314 A JP2016501314 A JP 2016501314A JP 2016501314 A JP2016501314 A JP 2016501314A JP 2016513643 A5 JP2016513643 A5 JP 2016513643A5
Authority
JP
Japan
Prior art keywords
protein
recombinant protein
tentacle
chromatography medium
anion exchange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513643A (ja
JP6457479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023682 external-priority patent/WO2014159441A1/en
Publication of JP2016513643A publication Critical patent/JP2016513643A/ja
Publication of JP2016513643A5 publication Critical patent/JP2016513643A5/ja
Application granted granted Critical
Publication of JP6457479B2 publication Critical patent/JP6457479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501314A 2013-03-14 2014-03-11 漏出したアフィニティ精製リガンドの除去 Active JP6457479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
US61/785,038 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (3)

Publication Number Publication Date
JP2016513643A JP2016513643A (ja) 2016-05-16
JP2016513643A5 true JP2016513643A5 (enExample) 2017-03-30
JP6457479B2 JP6457479B2 (ja) 2019-01-23

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501314A Active JP6457479B2 (ja) 2013-03-14 2014-03-11 漏出したアフィニティ精製リガンドの除去

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP3395423B1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK2969099T4 (enExample)
ES (2) ES2964601T3 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE038565T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL3395423T3 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI2969099T2 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964601T3 (es) 2013-03-14 2024-04-08 Amgen Inc Eliminación de ligando de purificación por afinidad filtrado
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3155009A1 (en) * 2014-06-13 2017-04-19 Lupin Limited Process for the purification of tnfr:fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6398962B1 (en) 1997-06-18 2002-06-04 Merck Kgaa Use of monolithic sorbents for preparative chromatographic separation
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2469815C (en) 2001-12-21 2011-05-03 Immunex Corporation Methods for purifying protein
MX2007011129A (es) * 2005-03-11 2007-11-06 Wyeth Corp Un metodo de cromatografia de particion debil.
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
US20120141497A1 (en) * 2009-03-11 2012-06-07 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
ES2603396T3 (es) * 2010-07-30 2017-02-27 Pfizer Inc Purificación en tándem de proteínas
WO2012176158A1 (en) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
AU2012282960A1 (en) * 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2773671B1 (en) * 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
ES2964601T3 (es) 2013-03-14 2024-04-08 Amgen Inc Eliminación de ligando de purificación por afinidad filtrado

Similar Documents

Publication Publication Date Title
JP2016513643A5 (enExample)
Yigzaw et al. Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification
JP2017508759A5 (enExample)
JP2014500311A5 (enExample)
RU2014111820A (ru) Способы элиминации вируса
JP2016530533A5 (enExample)
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
JP2010534336A5 (enExample)
JP2014501758A5 (enExample)
JP2016502843A5 (enExample)
JP2014502272A5 (enExample)
JP2017521389A5 (enExample)
US20110166332A1 (en) Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
US20120283419A1 (en) Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
JP2014532718A5 (enExample)
Dhadge et al. Magnetic aqueous two phase fishing: a hybrid process technology for antibody purification
JP2018516229A5 (enExample)
Bolton et al. Inactivation of viruses using novel protein A wash buffers
RU2011112989A (ru) Способы очистки однодоменных антигенсвязывающих молекул
HRP20180182T1 (hr) Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
JP2015503524A5 (enExample)
JP2018510867A5 (enExample)
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
JP2016519052A5 (enExample)